Valuation : Korro Bio, Inc.

Market Cap 190M 164M 154M 140M 264M 18.17B 265M 1.82B 711M 9.17B 714M 698M 30.41B P/E 2026 *
-2.42x
P/E 2027 * -2.85x
Enterprise Value 190M 164M 154M 140M 264M 18.17B 265M 1.82B 711M 9.17B 714M 698M 30.41B EV / Sales 2026 *
570x
EV / Sales 2027 * 168x
Free-Float
99.06%
Yield 2026 *
-
Yield 2027 * -
1 day-2.64%
1 week-2.05%
Current month+24.49%
1 month+28.20%
3 months-3.73%
6 months+6.43%
Current year+61.17%
1 week 12.66
Extreme 12.66
13.98
1 month 9.76
Extreme 9.76
14.18
Current year 7.82
Extreme 7.82
15.56
1 year 5.2
Extreme 5.2044
55.89
3 years 5.2
Extreme 5.2044
98
5 years 5.2
Extreme 5.2044
98
10 years 5.2
Extreme 5.2044
98
Date Insider Type Main position Quantity % Market Cap.
8/19/26
Atlas Venture Life Science Advisors LLC
SellCompany -28,468 0.1933%
8/11/26
Atlas Venture Life Science Advisors LLC
SellCompany -2,143 0.0146%
8/10/26
Lynx1 Capital Management LP
BuyCompany 1,462 0.0099%
Change 5-day change 1-year change 3-year change Capi.($)
-2.64%-2.05%-44.06% - 190M
-0.78%-1.42%+2.96%+21.65% 50.47B
-6.00%-0.75%+447.48%+535.14% 44.56B
-0.24%+0.74%+37.18%+16.26% 43.08B
-1.55%-2.07%+19.83%+71.70% 41.7B
-0.31%-0.83%+19.47%+48.24% 33.21B
-1.79%-3.24%+26.32%+125.06% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.63%+27.62% 14.58B
-1.66%-1.25%+78.49%+42.97% 13.92B
Average -1.64%-1.16%+66.59%+111.08% 27.47B
Weighted average by Cap. -1.70%-1.06%+96.17%+129.03%

Financials

2026 *2027 *
Net sales 333K 287K 269K 246K 463K 31.86M 465K 3.2M 1.25M 16.08M 1.25M 1.22M 53.32M 1.13M 977K 916K 836K 1.57M 108M 1.58M 10.86M 4.24M 54.68M 4.26M 4.16M 181M
Net income -83.64M -72.07M -67.58M -61.69M -116M -7.99B -117M -802M -313M -4.04B -314M -307M -13.38B -92.44M -79.66M -74.69M -68.18M -128M -8.84B -129M -886M -346M -4.46B -347M -340M -14.79B
Net Debt - -
Logo Korro Bio, Inc.
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Employees
57
Date Price Change Volume
26-08-28 US$12.91 -2.64% 67,368
26-08-27 US$13.26 -3.07% 48,569
26-08-26 US$13.68 -0.36% 41,275
26-08-25 US$13.73 +5.05% 79,709
26-08-24 US$13.07 -0.83% 70,368
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
12.91USD
Average target price
20.20USD
Spread / Average Target
+56.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KRRO Stock